Friday, 9 October 2015

Where does OPERA for the anti-CD20 come from.

Music to your ears.....but

Look at clinical trials.gov

A study of ocrelizumab in comparison with interferon with interferon beta-1a in patients with relapsing multiple sclerosis

now get OPERA out of that

A study of Ocrelizumab in comParison with interferon with intERferon beta-1a in patients with relApsing multiple sclerosis

Now how many ways can you do this?

Now make ORATORIO out of
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

Simples.

I asked the people at ECTRIMS2015 and they were not sure, and so we went to clinical trials to see if we could get the name, One person thought that it may be relate to music and this turns out to be the case. So thanks to Laura for contacting them

4 comments:

  1. I don't go to the opera and I don't care about going to the theatre to hear some oratorio.

    What I as an MSer care about is the pure and simple fact:

    if they suceeded for the first time to slow neurodegeneration (not just relapses) or if it's just another hype for shareholders.

    can someone answer this definitively cos I'm starting to get fed up with over-hyped nothings.

    ReplyDelete
    Replies
    1. MD's post was simply an answer to a question posed in the Google hangout.

      Delete
  2. You must not have seen my tweet - I got an official answer from Genentech, which said they stand for nothing (rather ironic) and are just names picked to go with the ORCHESTRA trial. I like your explanation much better.

    ReplyDelete
  3. You must not have seen my tweet - I got an official answer from Genentech, which said they stand for nothing (rather ironic) and are just names picked to go with the ORCHESTRA trial. I like your explanation much better.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.